Evidence map›Paper›PMID 36632750›Full record

ArticleJournal of Zhejiang University. Science. B2023

Targeting

Qiong Zhao, Luwen Zhang, Qiufen He, Hui Chang, Zhiqiang Wang, Hongcui Cao, Ying Zhou, Ruolang Pan, Ye Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Qiong ZhaoDepartment of Genetics, and Department of Genetic and Metabolic Disease, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
Luwen ZhangDepartment of Genetics, and Department of Genetic and Metabolic Disease, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
Qiufen HeDepartment of Genetics, and Department of Genetic and Metabolic Disease, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
Hui ChangDepartment of Genetics, and Department of Genetic and Metabolic Disease, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
Zhiqiang WangDepartment of Genetics, and Department of Genetic and Metabolic Disease, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China.
Hongcui CaoState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Ying ZhouXiangshan Hospital of TCM Medical and Health Group, Ningbo 315700, China.
Ruolang PanZhejiang Provincial Key Laboratory of Cell-Based Drug and Applied Technology Development, Hangzhou 311121, China. yechency@zju.edu.cn, panrl@zju.edu.cn.
Ye ChenDepartment of Genetics, and Department of Genetic and Metabolic Disease, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China. yechency@zju.edu.cn.
Children's Hospital of Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CNNingbo No.6 Hospital · CNZhejiang University of Technology · CN

Funding

the National Key Research and Development Program of China 2020YFA0113003 and 2018YFC1004803
6 · The paper itself

Abstract

Accumulating evidence has confirmed the links between transfer RNA (tRNA) modifications and tumor progression. The present study is the first to explore the role of tRNA methyltransferase 5 (TRMT5), which catalyzes the m1G37 modification of mitochondrial tRNAs in hepatocellular carcinoma (HCC) progression. Here, based on bioinformatics and clinical analyses, we identified that TRMT5 expression was upregulated in HCC, which correlated with poor prognosis. Silencing

Indexed as

Carcinoma, HepatocellularLiver NeoplasmstRNA MethyltransferasesCell HypoxiaCell Line, TumorGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitSignal TransductionHypoxia-Inducible Factor 1, alpha SubunitTRMT5 protein, humantRNA MethyltransferasesHepatocellular carcinoma (HCC)Hypoxia-inducible factor-1α (HIF-1α)Transfer RNA (tRNA)tRNA methyltransferase 5 (TRMT5)

Identifiers

PMID36632750
PMCPMC9837375
OpenAlexW4315752854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.